Dr. Baldwin serves as Co-founder and Director of the company. In 2015, Dr. Baldwin joined with Dr. Bo Liang to establish iVIEW Therapeutics, a company directed toward the development of novel formulations to overcome drug delivery issues.
Dr. Baldwin has spent 60 years in drug discovery and on novel technologies to increase the efficiency of the discovery process. While at Merck Research Laboratories, he made important contributions to the discovery and development of Trusopt and Cosopt, Edecrin, Aggrastat and Crixavan. His contributions in the area of Ophthalmology, are well known and were based on solving the vexing problem of arylsulfonamide’s bioavailability after topical administration.
After Merck, he became a founder and Chief Science Officer of Pharmacopeia Inc. where he pioneered the integration of combinatorial chemistry and high throughput screening into the drug discovery process. In 2001 he cofounded Vitae Pharmaceuticals where he was President and Chief Science Officer.
Dr. Baldwin was one of the first to recognize the drug discovery assets available in China. He was a founder of WuXi PharmaTech in Shanghai and served on the Board of Directors. More recently he became a Founder and Member of the Board for Hua Medicine in Shanghai and CarysBio in Foshan, China.
Dr. Baldwin obtained his PhD in Organic Chemistry from University of Minnesota. He has been recognized for his accomplishments by the American Chemical Society with the E.B. Hershberg Award and his nomination to the Medicinal Chemistry “Hall Of Fame”. He has also received the Philadelphia ACS Section Award and the 2012 PDDI Drug Discovery Award for Outstanding Contributions to Drug Discovery. Other Awards for outstanding achievement include those from the University of Minnesota, the University of Delaware and The Salesianum School. Dr. Baldwin has published over 150 scientific articles and is the inventor on over 250 issued U.S. patents. He has also served on the Advisory Council of the University of Minnesota’s Institute of Technology and on the Advisory Board for the Chemistry/Biochemistry Department University of Delaware. Dr. Baldwin has been elected to the Joseph Priestley Society of the Chemical Heritage Foundations and serves on Foundation’s Board of Overseers.
• Kittner Distinguished Professor and Chairman of the UNC Department of Ophthalmology
• MD, Harvard Medical School; MPH, Johns Hopkins Bloomberg School of Public Health
• Ophthalmology residency at the University of Pennsylvania; Fellowship in Glaucoma at the University of Miami, School of Medicine
• Principal investigator in a number of clinical trials including the Ocular Hypertension Treatment Study
• Published widely in the field of glaucoma with over 200 peer-reviewed journal articles
• Ophthalmologist at Scripps Health specializing in advanced corneal, cataract and refractive surgery
• MD, Medical College of Ohio
• Residency, chief residency, and fellowship in cornea, external disease and refractive surgery at the University of Pittsburgh
• Dr. Mah treats corneal dystrophies as well as keratoconus and other corneal thinning disorders
• International expert on corneal infections (bacterial, viral, fungal, and parasitic)
Website Language: 
5 Cedarbrook Drive, Suite 2